undamentalytics Newsletter
Sign in

Rigel Pharmaceuticals Inc revenue

Rigel Pharmaceuticals Inc's revenue was $294m in fiscal 2025, up 64.1% on the year before. Since fiscal 2016 ($20.4m) it has grown at a compound 34.5% a year. Over the last twelve months it was $277m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue2044559109149120117179294277
Growth on the year before—−78.0%+892.6%+33.2%+83.2%+37.4%−19.4%−2.8%+53.4%+64.1%—
Gross profit——4458108148118110161275253
Gross margin——99.4%98.5%99.2%99.3%98.5%93.9%89.6%93.3%91.4%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Gross Product $310M ▲ 47.7%
Products $232M ▲ 60.1%
Contract Revenues From Collaborations $62M ▲ 80.5%
Release of Share Cost Liability $40M —
Royalty Delivery of Drug Supplies and Others $19.1M ▼ 6.5%
Development Milestones $3M —
Government Contract $265,000 —
Licenses $0 ▼ 100.0%
Discounts and Allowances -$78M —

These categories overlap or exclude eliminations, so shares aren't shown.

From Rigel Pharmaceuticals Inc's 10-K filed March 3, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Rigel Pharmaceuticals Inc $277m 3.3% 29.8%
Harrow, Inc. $276m 21.1% 39.0%
Evolus, Inc. $316m 13.9% 23.4%
Aurora Cannabis Inc $232m 11.7% —
Vanda Pharmaceuticals Inc. $229m 8.1% 2.7%
Xeris Biopharma Holdings, Inc. $335m 36.3% 35.8%

Compare with peers

Head to head: HROW vs RIGLEOLS vs RIGLACB vs RIGL

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Rigel Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Rigel Pharmaceuticals Inc.